{
    "relation": [
        [
            "Published Date",
            "Jan 28, 2015",
            "Oct 9, 2014",
            "Aug 13, 2014",
            "Jul 11, 2014",
            "Aug 17, 2009",
            "Jul 22, 2009",
            "Sep 4, 2008",
            "Feb 8, 2008",
            "Oct 25, 2007",
            "Nov 17, 2006"
        ],
        [
            "Version",
            "11 (current)",
            "10",
            "9",
            "8",
            "7",
            "6",
            "4",
            "3",
            "2",
            "1"
        ],
        [
            "Files",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download",
            "download"
        ]
    ],
    "pageTitle": "DailyMed - SYMLINPEN- pramlintide acetate injection",
    "title": "",
    "url": "http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2262f20-bedb-43d9-b274-6ce275b0a69e",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990112.50/warc/CC-MAIN-20150728002310-00027-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 59045059,
    "recordOffset": 59001013,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{54338=Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088., 196524=To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\u00a0, 130973=SYMLIN is formulated as a clear, isotonic, sterile solution for subcutaneous administration. The disposable multidose SymlinPen\u00ae pen-injector contains 1000 mcg/mL of pramlintide (as acetate). The formulation contains 2.25 mg/mL of metacresol as a preservative, D-mannitol as a tonicity modifier, acetic acid, sodium acetate as pH modifiers, and water for injection. SYMLIN has a pH of approximately 4.0., 112847=When 1000 mg acetaminophen was given within 0, 1, and 2 hours after a 120 mcg SYMLIN injection in patients with type 2 diabetes (n=24), acetaminophen Cmax decreased by 29%, 23%, and 20%, respectively compared to placebo. The time to maximum plasma concentration or Tmax increased by 72, 48, and 48 minutes, respectively. SYMLIN did not significantly affect acetaminophen Tmax or Cmax when acetaminophen was administered 1 to 2 hours before SYMLIN injection. SYMLIN did not affect acetaminophen AUC regardless of the time of acetaminophen administration in relation to SYMLIN injection., 27351=Revised August 2014, 202460=Warnings and Precautions (5.3) 8/2014, 1166=1000 mcg/mL, 2.7 mL, 194333=Revised: 8/2014, 2928=1000 mcg/mL, 1.5 mL, 120598=11970, 51278=Revised: August 2014, 107454=A total of 2333 patients with type 1 diabetes and 1852 patients with type 2 diabetes received SYMLIN in controlled clinical trials., 134243=No consistent differences in the efficacy and safety of SYMLIN have been observed between men and women in SYMLIN clinical trials (n=2799 for male and n=2085 for female).}",
    "textBeforeTable": "Number of versions: 10 SYMLINPEN- pramlintide acetate injection View Label Archives for this drug View Label Archives, RxNorm, Get Label RSS Feed More Info on this Drug Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary Related Resources Boxed Warnings, Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk Safety (also available in the left menu) Find additional resources Close All Sections View All Sections Close Registrant -\u00a0AstraZeneca PLC (230790719) Labeler -\u00a0Amylin Pharmaceuticals, LLC (196877526) 07/31/2017 03/16/2005 NDA021332 NDA Marketing End Date Marketing Start Date Application Number or Monograph Citation Marketing Category Marketing Information",
    "textAfterTable": "RxNorm SYMLINPEN- pramlintide acetate injection RxCUI RxNorm NAME RxTTY 1 861042 pramlintide acetate 1000 MCG/ML in 2.7 ML Pen Injector PSN 2 861042 2.7 ML pramlintide acetate 1 MG/ML Pen Injector SCD 3 861042 pramlintide acetate 2.7 MG per 2.7 ML Pen Injector SY 4 861042 pramlintide acetate 2700 MCG per 2.7 ML Pen Injector SY 5 861043 SymlinPen 120 1000 MCG/ML in 2.7 mL Pen Injector PSN 6 861043 2.7 ML pramlintide acetate 1 MG/ML Pen Injector [Symlin] SBD 7 861043 2.7 ML Symlin 1 MG/ML Pen Injector SY 8 861043 Symlin 1 MG/ML 2.7 ML Prefilled Pen SY 9 861043 SymlinPen 120 1000 MCG per ML Pen Injector, 2.7 ML SY 10 861044 pramlintide acetate 1000 MCG/ML in 1.5 ML Pen Injector PSN 11 861044 1.5 ML pramlintide acetate 1 MG/ML Pen Injector SCD 12 861044 1.5 ML pramlintide acetate 1000 MCG/ML Pen Injector SY 13 861044 pramlintide acetate 1.5 MG per 1.5 ML Pen Injector SY 14 861044 pramlintide acetate 1500 MCG per 1.5 ML Pen Injector SY 15",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}